At the Precision Medicine World Conference, Invitae executives noted that early experience in the genetic screening pilot found more people received positive results than previously expected.
The team hopes to commercialize the technology by producing cost-effective tests to rapidly diagnose common upper respiratory viral pathogens.
The agency is excluding certain advanced diagnostic lab tests and molecular pathology tests from a billing regulation that created administrative headaches for many labs.
The British molecular genetics company recently announced a menu update for its SureSeq myPanel NGS Custom Cancer Panel offering.
Angsana will support a Phase 2 basket trial for a tyrosine kinase inhibitor that targets tumors harboring TRK, ROS1, and ALK fusions.
The company is preparing a blood-based test for early-stage pancreatic cancer that it hopes to have on the market by 2019.
The company's new blood-based test is the first clinical test offering that the company will be offering at its New York-based CLIA laboratory.
N-of-One will identify the most relevant therapeutic options for each patient tested with Admera's 64-gene oncology panel.
Full-year revenues fell 22 percent, which the company said was due to a decrease in the number of kits being returned for processing.
The company's recent experience demonstrates the impasse between genetic test developers and payors about the types of clinical evidence needed for coverage.
23andMe and Airbnb have partnered to offer "heritage travel," according to Venture Beat.
China may include regulations protecting genes and embryos in its update of its civil code, Nature News reports.
In Nature this week: exome sequence analysis of individuals with type 2 diabetes, genomic prediction of maize yield across environments, and more.
NPR reports on efforts to engineer bacteriophages to destroy antibiotic-resistance bacteria.